Bio-Rad Labs downgraded by Citigroup with a new price target
$BIO
Biotechnology: Laboratory Analytical Instruments
Industrials
Citigroup downgraded Bio-Rad Labs from Buy to Neutral and set a new price target of $365.00 from $400.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/1/2024 | $350.00 → $400.00 | Neutral → Buy | Citigroup |
| 8/28/2024 | $340.00 | Equal Weight | Wells Fargo |
| 6/3/2024 | $315.00 | Hold | Jefferies |
| 4/3/2024 | $400.00 → $365.00 | Buy → Neutral | Citigroup |
| 12/7/2023 | $395.00 | Buy | UBS |
| 6/16/2023 | $550.00 | Overweight | Wells Fargo |
| 12/7/2022 | $565.00 | Outperform | RBC Capital Mkts |
| 8/25/2022 | $715.00 | Outperform | Credit Suisse |
The stock market is up solidly this year, thanks to expectations of rate cuts by the Federal Reserve amid easing inflationary pressure, strong corporate earnings and optimism over the potential of artificial intelligence technology’s potential. Building On Gains: The S&P 500 Index, a measure of broader market performance, has gained a robust 14.48% so far this year, and it is up 3.92% for the second quarter. The index last hit a record closing high (5,487.03) on June 18, and breached the 5,500 mark intraday on June 20. Since then, the broader gauge has been going about a consolidation move. The SPDR S&P 500 ETF Trust (NYSE:SPY), an exchange-traded fund that tracks the performance of th
Jefferies assumes Bio-Rad Laboratories (NYSE:BIO) with a Hold rating and lowers Price Target of $315.
-Reuters
Citigroup upgraded Bio-Rad Labs from Neutral to Buy and set a new price target of $400.00 from $350.00 previously
Wells Fargo initiated coverage of Bio-Rad Labs with a rating of Equal Weight and set a new price target of $340.00
Jefferies resumed coverage of Bio-Rad Labs with a rating of Hold and set a new price target of $315.00
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2024. Third-quarter 2024 total net sales were $649.7 million, an increase of 2.8 percent compared to $632.1 million reported for the third quarter of 2023. On a currency-neutral basis, quarterly sales increased 3.4 percent compared to the same period in 2023. The increase in net sales was driven by higher sales in our Clinical Diagnostics segment. Life Science segment net sales for the third quarter were $260.9 million, a decrease of 1.0 percent compared to the same period in 2023. On a currency-neutr
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2024 on Wednesday, October 30, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, dial 800-579-2543 within the U.S. or 785-424-1789 outside the U.S., access code: BIORAD. A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for u
Interest in kidney transplant assay represents approximately 25% of US transplant volumeCompany lays out land and expand strategy in transplant IRVINE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, today published its second quarter 2024 results and the following letter to shareholders. Dear shareholders,We are thrilled to report that we have successfully launched GraftAssure™, which is our research-use-only assay that can detect early evidence of graft organ damage in a patient's blood. On July 11, 2024, our GraftAssure assay was run at a major metropolitan transplant center and research university in the northeast United State
8-K - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)
10-Q - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)
8-K - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will host one-on-one meetings with analysts and investors during Citi's 2024 Global Healthcare Conference in Miami, FL, December 3-5, 2024. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE:BIO) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales opera
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the UBS Global Healthcare Conference on Wednesday, November 13, 2024, at 1:15 PM Pacific Time. A live webcast and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad's website at bio-rad.com. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE:BIO) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2024. Third-quarter 2024 total net sales were $649.7 million, an increase of 2.8 percent compared to $632.1 million reported for the third quarter of 2023. On a currency-neutral basis, quarterly sales increased 3.4 percent compared to the same period in 2023. The increase in net sales was driven by higher sales in our Clinical Diagnostics segment. Life Science segment net sales for the third quarter were $260.9 million, a decrease of 1.0 percent compared to the same period in 2023. On a currency-neutr
SC 13G/A - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)
SC 13G - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)
NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that Jon DiVincenzo will join the company as President and Chief Operating Officer, effective September 9, 2024, replacing Andy Last, who is retiring. Mr. DiVincenzo joins Bio-Rad from Labcorp Holdings Inc., a global provider of comprehensive laboratory services, where he held various global operational and commercial leadership roles across the company's several business units. Most recently, he served as Executive Vice President and President, Central Laboratories and International. Prior to LabCorp, Mr. DiVincenzo was President of the Environmental Health D
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that Roop K. Lakkaraju will join the company as its new Executive Vice President and Chief Financial Officer, effective April 15, 2024. Mr. Lakkaraju joins Bio-Rad from Benchmark Electronics, a multi-national leader in electronics manufacturing services, where he served as Executive Vice President and Chief Financial Officer responsible for all finance-related functions supporting the company's global operations since 2018. Prior to Benchmark, he held Chief Financial Officer and senior operational roles at several large, multinational companies including Suppo
3 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)
4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)
4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)